Leukemia Clinical Trials in Los Angeles

Showing 1081-1100 of 1,166 trials

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT00112983

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eculizumab may prevent leukemia and stop the destruction of red blood cells in patients with paroxysmal nocturnal hemoglobinuria. PURPOSE: This randomized phase III trial is studying how well eculizumab works in treating patients with paroxysmal nocturnal hemoglobinuria.

Leukemia

Jonsson Comprehensive Cancer CenterStarted Nov 2004

Los Angeles, California, United States

COMPLETEDPhase 1/2< 1 mile

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

NCT00015834

Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells

Blastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveRelapsing Chronic Myelogenous Leukemia

National Cancer Institute (NCI)46 participantsStarted May 2001

Los Angeles, California, United States

COMPLETEDPhase 3< 1 mile

Iressa Expanded Access Program (EAP)

NCT00034879

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.

CarcinomaNon-small-cell LungMetastases+1 more

AstraZenecaStarted Aug 2000

Alabaster, Alabama, United States • Anniston, Alabama, United States • Birmingham, Alabama, United States +623 more locations

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Iressa Expanded Access Program (EAP)

Leukemia Trials in Other Cities

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

S9912 Combination Chemo in Stage III Ovarian Cancer,

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Topotecan in Treating Children With Refractory Leukemia

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Other Conditions in Los Angeles